Research Summary

Analyzed using Evidence Intelligence™

Clazakizumab reduces hs-CRP in diabetes patients

Last updated July 6, 2026

Key finding

Predicted that all doses would result in the majority (≥ 80%) of subjects experiencing at least an 80% decrease in baseline hs-CRP.

This study evaluated the impact of Clazakizumab on high-sensitivity C-reactive protein (hs-CRP) levels in patients with cardiovascular disease and diabetes, finding significant decreases in hs-CRP levels with treatment.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

Clinical relevance

Reducing hs-CRP levels is clinically significant as it may lower the risk of cardiovascular events in patients with diabetes and cardiovascular disease. This study suggests that Clazakizumab could be an effective treatment option to manage inflammation in these high-risk populations.

Keep in mind

Effectiveness data were unclear for some outcomes. The study's population may not be generalizable to all patients with cardiovascular disease. Limited information on long-term effects of Clazakizumab.

Published in

Journal Reference

Publication details and source links for this paper.

Venkateswari YM, Thomas K, Laura ES, et al. Impact of Clazakizumab on High-Sensitivity C-Reactive Protein in Patients with Cardiovascular Disease and Diabetes. Clinical and Translational Science. 2025;18(11):e70381. doi:10.1111/cts.70381

View DOI View on PubMed View on PMC

Main Effects

Clazakizumab resulted in an 80% decrease in baseline hs-CRP levels in the majority of subjects.

The proportion of subjects with hs-CRP < 2 mg/L was predicted to be 82.6% in the highest dose group.

No significant change in hs-CRP levels was observed in the placebo group.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Clazakizumab and C-reactive protein, Proportion of subjects with hs-CRP < 2 mg/L.

This study contributes evidence to

Intervention

Clazakizumab

Outcome

C-reactive protein

Evidence topic

Inflammatory and Vascular Markers

Primary intervention

Clazakizumab

Primary outcomes

C-reactive protein
Proportion of subjects with hs-CRP < 2 mg/L

Evidence topics

Inflammatory and Vascular Markers

Primary intervention

Clazakizumab

Primary outcomes

C-reactive protein Proportion of subjects with hs-CRP < 2 mg/L

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 55

Why it is useful

Contributes to 2 evidence relationships
Includes primary outcome data
Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence topic

Inflammatory and Vascular Markers

matched_outcome

Core evidence

Study findings

The primary outcomes reported in this study.

C-reactive protein

Clazakizumab → C-reactive protein

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Proportion of subjects with hs-CRP < 2 mg/L

Clazakizumab → Proportion of subjects with hs-CRP < 2 mg/L

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Suggest

Majority of subjects on Clazakizumab experienced at least an 80% decrease in hs-CRP.
82.6% of subjects in the highest dose group had hs-CRP < 2 mg/L.
No significant change in hs-CRP in the placebo group.

Who this applies to

Adults with cardiovascular disease.
Patients with diabetes, particularly those at high risk for cardiovascular events.

Keep in Mind

Results may not apply to populations outside the study's criteria.
Further research is needed to confirm long-term benefits of Clazakizumab.
Effectiveness claims are based on predicted outcomes and may require additional validation.

Between the Lines

Effectiveness data were unclear for some outcomes.
The study's population may not be generalizable to all patients with cardiovascular disease.
Limited information on long-term effects of Clazakizumab.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Clazakizumab and Inflammatory Markers, Clazakizumab and Proportion of subjects with hs-CRP < 2 mg/L.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

Clazakizumab → Inflammatory Markers

Medications

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

View evidence

Medications

Detailed evidence

Clazakizumab → Proportion of subjects with hs-CRP < 2 mg/L

Medications

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

View evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

Clazakizumab Evidence Hub

All studies on Clazakizumab

1 studies

intervention_hub

Contributes to Clazakizumab evidence base.

Inflammatory Markers Evidence Hub

All studies measuring Inflammatory Markers

1 studies

outcome_hub

Measures Inflammatory Markers as a key outcome.

Proportion of subjects with hs-CRP < 2 mg/L Evidence Hub

All studies measuring Proportion of subjects with hs-CRP < 2 mg/L

1 studies

outcome_hub

Measures Proportion of subjects with hs-CRP < 2 mg/L as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explore more in Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Clazakizumab and C-reactive protein

Intervention: ClazakizumabOutcome: C-reactive protein

1 results

All studies on Clazakizumab and Proportion of subjects with hs-CRP < 2 mg/L

Intervention: ClazakizumabOutcome: Proportion of subjects with hs-CRP < 2 mg/L

1 results

All studies on Clazakizumab

Intervention: Clazakizumab

1 results

All studies measuring C-reactive protein

Outcome: C-reactive protein

1 results

All studies measuring Proportion of subjects with hs-CRP < 2 mg/L

Outcome: Proportion of subjects with hs-CRP < 2 mg/L

1 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Clazakizumab improve c-reactive protein?

Emerging Evidence

Clazakizumab appears to improve C-reactive protein.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
C-reactive protein
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Clazakizumab improve proportion of subjects with hs-crp < 2 mg/l?

Emerging Evidence

Clazakizumab appears to improve Proportion of subjects with hs-CRP < 2 mg/L.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Proportion of subjects with hs-CRP < 2 mg/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Inflammatory and Vascular Markers Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Clazakizumab and C-reactive protein All studies on Clazakizumab and Proportion of subjects with hs-CRP < 2 mg/L

Related research

Read related research summaries.

NSPT improves plaque index and glycemic control in diabetes.BL21 Probiotic Improves Glycemic Control in Type 2 Diabetes Combining Exercise and Polyphenols Improves Glycemic Control in Prediabetes Cranberry juice with omega-3 improves inflammatory markers in diabetes Curcumin may improve inflammation and glycemic control in diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.